Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer
Resolution Therapeutics has strengthened its leadership team with two key appointments: Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer. The appointments follow the successful dosing of the first patient in the company's Phase I/II EMERALD study.
Lucy Singah brings over 20 years of corporate and strategic finance experience from companies including Echopoint Medical, GSK, and EY. Daniel Kennedy, with more than 20 years of business development experience, joins from Immunocore (NASDAQ: IMCR) and previously led deals at Achillion Pharmaceuticals, including its $930 million acquisition by Alexion.
The company will host an R&D Webinar on September 17, 2025, featuring clinical hepatologists to discuss its regenerative macrophage therapy (RMT) platform for inflammatory and fibrotic diseases.
Resolution Therapeutics ha rafforzato il proprio team dirigente con due nomine chiave: Lucy Singah come Chief Financial Officer e Daniel Kennedy come Chief Business Officer. Le nomine seguono il primo dosaggio riuscito del paziente nello studio di fase I/II EMERALD dell'azienda.
Lucy Singah vanta oltre 20 anni di esperienza in finanza aziendale e strategica in realtà come Echopoint Medical, GSK e EY. Daniel Kennedy, con più di 20 anni di esperienza nello sviluppo business, arriva da Immunocore (NASDAQ: IMCR) e in precedenza ha guidato operazioni presso Achillion Pharmaceuticals, tra cui la sua acquisizione da $930 milioni da parte di Alexion.
L'azienda terrà un webinar R&D il 17 settembre 2025, con epatologi clinici che discuteranno la sua piattaforma di terapia con macrofagi rigenerativi (RMT) per malattie infiammatorie e fibrotiche.
Resolution Therapeutics ha reforzado su equipo directivo con dos incorporaciones clave: Lucy Singah como Chief Financial Officer y Daniel Kennedy como Chief Business Officer. Las designaciones se producen tras la dosificación exitosa del primer paciente en el estudio Fase I/II EMERALD de la compañía.
Lucy Singah aporta más de 20 años de experiencia en finanzas corporativas y estratégicas en empresas como Echopoint Medical, GSK y EY. Daniel Kennedy, con más de 20 años en desarrollo de negocio, se incorpora desde Immunocore (NASDAQ: IMCR) y anteriormente lideró acuerdos en Achillion Pharmaceuticals, incluida su adquisición por $930 millones por parte de Alexion.
La compañía celebrará un webinar de I+D el 17 de septiembre de 2025, con hepatólogos clínicos que debatirán su plataforma de terapia con macrófagos regenerativos (RMT) para enfermedades inflamatorias y fibróticas.
Resolution Therapeutics가 핵심 임원 두 명을 영입하며 리더십을 강화했습니다: Lucy Singah가 최고재무책임자(CFO), Daniel Kennedy가 최고비즈니스책임자(CBO)로 선임되었습니다. 이번 임명은 회사의 1/2상 EMERALD 연구에서 첫 환자 투여가 성공적으로 이루어진 후 발표되었습니다.
Lucy Singah는 Echopoint Medical, GSK, EY 등에서의 경력을 포함해 20년 이상의 기업 및 전략 재무 경험을 보유하고 있습니다. Daniel Kennedy는 20년 이상의 사업개발 경험을 가지고 Immunocore(NASDAQ: IMCR)에서 합류했으며, 이전에는 Achillion Pharmaceuticals에서 거래를 이끌어 Alexion에 의한 $930 million 규모의 인수를 포함한 성과를 기록했습니다.
회사는 2025년 9월 17일에 임상 간질환 전문의들이 참여하는 R&D 웨비나를 개최해 염증성 및 섬유성 질환을 위한 재생성 마크로파지 치료(RMT) 플랫폼을 논의할 예정입니다.
Resolution Therapeutics a renforcé son équipe dirigeante avec deux nominations clés : Lucy Singah en tant que Chief Financial Officer et Daniel Kennedy en tant que Chief Business Officer. Ces nominations interviennent après l'administration réussie du premier patient dans l'étude de phase I/II EMERALD de la société.
Lucy Singah apporte plus de 20 ans d'expérience en finance d'entreprise et stratégique, acquise chez Echopoint Medical, GSK et EY. Daniel Kennedy, fort de plus de 20 ans d'expérience en développement commercial, rejoint Immunocore (NASDAQ: IMCR) et a précédemment mené des opérations chez Achillion Pharmaceuticals, dont son acquisition par Alexion pour $930 millions.
La société organisera un webinaire R&D le 17 septembre 2025, réunissant des hépatologues cliniques pour discuter de sa plateforme de thérapie par macrophages régénératifs (RMT) pour les maladies inflammatoires et fibrosantes.
Resolution Therapeutics hat seine Führungsmannschaft mit zwei Schlüsselernennungen gestärkt: Lucy Singah als Chief Financial Officer und Daniel Kennedy als Chief Business Officer. Die Ernennungen erfolgen nach der erfolgreichen Dosierung des ersten Patienten in der Phase-I/II-Studie EMERALD des Unternehmens.
Lucy Singah bringt über 20 Jahre Erfahrung in Unternehmens- und Strategiefinanzen aus Unternehmen wie Echopoint Medical, GSK und EY mit. Daniel Kennedy, mit mehr als 20 Jahren Erfahrung in der Geschäftsentwicklung, wechselt von Immunocore (NASDAQ: IMCR) und leitete zuvor Transaktionen bei Achillion Pharmaceuticals, darunter die $930 Millionen Übernahme durch Alexion.
Das Unternehmen wird am 17. September 2025 ein R&D-Webinar veranstalten, bei dem klinische Hepatologen seine Plattform für regenerative Makrophagen-Therapie (RMT) bei entzündlichen und fibrotischen Erkrankungen diskutieren werden.
- Strategic strengthening of executive team with experienced CFO and CBO appointments
- Clinical progress with first patient dosed in Phase I/II EMERALD study
- New CBO brings track record of successful M&A deals, including $930M Achillion acquisition
- None.
- Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution.
- Accomplished Chief Business Officer will drive business development and partnering deals.
- Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study.
Dr. Amir Hefni, Chief Executive Officer of Resolution Therapeutics, said: "We are delighted to welcome Lucy and Dan to our leadership team at this exciting time in the Company's journey, having recently announced the successful dosing of the first patient with RTX001. I look forward to working with the strengthened executive team to deliver on our vision to transform patient outcomes by pioneering regenerative macrophage therapy (RMT) in inflammatory and fibrotic diseases."
Lucy is a seasoned finance leader with over 20 years of corporate and strategic finance experience, across both
Lucy Singah, newly appointed Chief Financial Officer of Resolution Therapeutics, said: "I am honoured to join Resolution at such a pivotal stage in the Company's development. I look forward to collaborating with the team and leveraging my experience to advance the Company s financial goals and drive RTX001 through the clinic."
Daniel is an accomplished business development executive with over 20 years of experience building partnerships, leading licensing deals, and driving strategic transactions in pharma and biotech. Previously he served as Vice President, Business Development at Immunocore plc (NASDAQ: IMCR), and led business development and alliance management at Achillion Pharmaceuticals, prior to its acquisition by Alexion Pharmaceuticals (NASDAQ: ALXN) for
Daniel Kennedy, newly appointed Chief Business Officer of Resolution Therapeutics, said: "I am proud to be joining a company with such a distinguished approach to treat inflammatory and fibrotic diseases. I look forward to supporting the Company as it grows, and continues to enrol and treat patients, driving its mission forward."
Resolution is hosting an R&D Webinar on Wednesday 17th September 2025 at 2pm BST / 9am ET / 6am PT alongside world leading clinical hepatologists.
Please use the following link to register. A replay will be available on the News page of the Resolution Website following the event's completion.
NOTES TO EDITORS
About RTX001
RTX001 is an engineered autologous regenerative macrophage therapy with enhanced anti-fibrotic and anti-inflammatory effects. The product candidate is engineered with IL-10-MMP9 mRNA to enhance the natural regenerative properties of macrophages for superior efficacy and durability. RTX001 is being tested in the Phase 1/2 study called 'EMERALD', an open-label first-in-human study in end-stage liver disease measuring clinical events as the primary efficacy endpoint. The EMERALD Phase 1/2 study is now recruiting.
About Resolution Therapeutics
Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases. The Company leverages its proprietary platform to develop macrophages with pro-regenerative properties for superior patient outcomes. Resolution's initial focus is on developing RTX001, its lead product with first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages, to treat patients with end-stage liver disease. The Company is also advancing efforts to expand the potential of its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes's lab at the University of
View original content:https://www.prnewswire.com/news-releases/resolution-therapeutics-appoints-lucy-singah-as-chief-financial-officer-and-daniel-kennedy-as-chief-business-officer-302551289.html
SOURCE Resolution Therapeutics
FAQ
Who are the new executives joining Resolution Therapeutics in September 2025?
What is Lucy Singah's experience before joining Resolution Therapeutics?
What significant deals has Daniel Kennedy been involved with?
When is Resolution Therapeutics' R&D Webinar scheduled for?
What is Resolution Therapeutics' main therapeutic focus?
